Biotechnology
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.